Keqi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keqi Wang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Fen Xie
Department of Gastroenterology, Changzheng Hospital Naval Medical University Shanghai China
2 shared publications Anan Liu
Second Mil Med Univ, Changzheng Hosp, Dept Pancreat Biliary Surg, Fengyang Rd 415, Shanghai 200003, Peoples R China
1 shared publication- Chang-Peng Zhu
Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China
1 shared publication Chen-Hong Ding
Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication- Chenghao Shao
Department of Pancreatic-biliary Surgery, Shanghai Changzheng Hospital, Shanghai, China
1 shared publication Chenhong Ding
Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China
1 shared publication
Latest Publications
- 12 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 515-527
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid
- 12 May 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 515-527
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid
- Open Access
- 1 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 913-929
Blocking TRIM47-mediated HNF4α degradation suppresses hepatocellular carcinoma progression
- 1 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 913-929
Open AccessBlocking TRIM47-mediated HNF4α degradation suppresses hepatocellular carcinoma progression
- Open Access
- 1 March 2021
- Published by AME Publishing Company in Gland Surgery
- Vol. 10 (3) , 1104-1117
Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysis
Background: Pancreatic cancer (PC) is one of the most invasive and metastatic neoplasms among the fatal malignancies of the digestive system. Abnormal expression of genes and long non-coding RNAs (lncRNAs) are reportedly linked to multiple cancers. However, the lncRNA-mRNA expression profiles and their molecular mechanisms in PC progression are poorly known. This study aimed to map the hub genes and lncRNAs which might play core roles in the development of PC. Methods: This study used microarray expression analysis to screen for both differentially expressed genes (DEGs) and differentially expressed lncRNAs (DElncRNAs) between PC and matched adjacent non-tumor (AN) tissues. In order to clarify the functional classification of DEGs, we conducted GO and KEGG pathway enrichment analyses via the Enrichr database. LncRNA-mRNA co-expressed networks were also constructed to explore the probable core regulating DEGs and DElncRNAs. Subsequently, the hub genes and lncRNAs were validated via the ONCOMINE and GEPIA databases and the co-expressed networks. Results: By analyzing an mRNA-lncRNA microarray, we identified 943 mRNAs and 1,138 lncRNAs differentially expressed in PC tumors compared with the matched AN tissues. GO analysis confirmed that both up-regulated and down-regulated DEGs were enriched in multiple terms. The KEGG pathways enrichment analyses revealed that DEGs were mostly enriched in the focal adhesion and glutathione metabolism pathways, amongst others. Co-expressed networks were established to reveal the differential interactions between DEGs and DElncRNAs, and to indicate the core regulatory factors located at the core nodes of the co-expressed networks. The expression levels of potential core-regulating DEGs were validated by the GEPIA and ONCOMINE databases, and the relationship between overall survival and tumor stage and the potential core-regulating DEGs was analyzed using the GEPIA database. As a result, five genes and sixteen lncRNAs were finally considered as the hub transcripts in PC. Conclusions: This study identified DEGs and DElncRNAs between PC tumors and matched AN tissues, and these transcripts were connected with malignant phenotypes in PC through different BPs and signaling pathways. Furthermore, five hub genes and sixteen lncRNAs were identified, which are expected to represent candidate diagnostic biomarkers or potential therapeutic targets for PC.
- 1 March 2021
- Published by AME Publishing Company in Gland Surgery
- Vol. 10 (3) , 1104-1117
Open AccessIdentification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysis
Background: Pancreatic cancer (PC) is one of the most invasive and metastatic neoplasms among the fatal malignancies of the digestive system. Abnormal expression of genes and long non-coding RNAs (lncRNAs) are reportedly linked to multiple cancers. However, the lncRNA-mRNA expression profiles and their molecular mechanisms in PC progression are poorly known. This study aimed to map the hub genes and lncRNAs which might play core roles in the development of PC. Methods: This study used microarray expression analysis to screen for both differentially expressed genes (DEGs) and differentially expressed lncRNAs (DElncRNAs) between PC and matched adjacent non-tumor (AN) tissues. In order to clarify the functional classification of DEGs, we conducted GO and KEGG pathway enrichment analyses via the Enrichr database. LncRNA-mRNA co-expressed networks were also constructed to explore the probable core regulating DEGs and DElncRNAs. Subsequently, the hub genes and lncRNAs were validated via the ONCOMINE and GEPIA databases and the co-expressed networks. Results: By analyzing an mRNA-lncRNA microarray, we identified 943 mRNAs and 1,138 lncRNAs differentially expressed in PC tumors compared with the matched AN tissues. GO analysis confirmed that both up-regulated and down-regulated DEGs were enriched in multiple terms. The KEGG pathways enrichment analyses revealed that DEGs were mostly enriched in the focal adhesion and glutathione metabolism pathways, amongst others. Co-expressed networks were established to reveal the differential interactions between DEGs and DElncRNAs, and to indicate the core regulatory factors located at the core nodes of the co-expressed networks. The expression levels of potential core-regulating DEGs were validated by the GEPIA and ONCOMINE databases, and the relationship between overall survival and tumor stage and the potential core-regulating DEGs was analyzed using the GEPIA database. As a result, five genes and sixteen lncRNAs were finally considered as the hub transcripts in PC. Conclusions: This study identified DEGs and DElncRNAs between PC tumors and matched AN tissues, and these transcripts were connected with malignant phenotypes in PC through different BPs and signaling pathways. Furthermore, five hub genes and sixteen lncRNAs were identified, which are expected to represent candidate diagnostic biomarkers or potential therapeutic targets for PC.